HER2Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer
Federico Cappuzzo, Lynne Bemis, Marileila Varella‐Garcia · New England Journal of Medicine · 2006
To the Editor: Trastuzumab is a monoclonal antibody against HER2, a member of the epidermal growth factor receptor (EGFR) family, that improves the outcome of HER2-positive breast cancer.1 Preclinical data have demonstrated that trastuzumab is effective in non–small-cell lung cancer, with additive or synergistic effects with various cytotoxic agents. However, trials of trastuzumab or other HER2-targeted agents, such as pertuzumab, failed to demonstrate clinical benefit in non–small-cell lung cancer when administered as monotherapy or combined with chemotherapy.2 In these studies, HER2 status was assessed by immunohistochemical analysis, a method that is not optimal.3 Moreover, the few patients whose tumors had . . .
Cited by 216 works. doi:10.1056/nejmc060020 Open-access PDF
Authors
References
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
- Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
- Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
- Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer